Fig. 8: SPRY2 is required to stabilize and regulate signaling downstream of the MET receptor. | Cell Death & Disease

Fig. 8: SPRY2 is required to stabilize and regulate signaling downstream of the MET receptor.

From: SPRY2 is a novel MET interactor that regulates metastatic potential and differentiation in rhabdomyosarcoma

Fig. 8

MAPK signaling transduced by aberrant MET activation and sustained by SPRY2 mediated stabilization of the MET receptor inhibits myogenic differentiation and confers metastatic characteristics on RMS cells (a). Silencing MET induces differentiation and reduces the metastatic potential of RMS cells by dampening the MAPK signaling (b). Silencing SPRY2 decreases MET stability and results in reduced MAPK signaling, thereby recapitulating the effects of MET silencing in RMS cells (b). Proteasomal degradation is the preferred pathway of MET degradation in ERMS (RD) cells while lysosome mediated degradation is the preferred pathway of MET degradation in ARMS (SJRH30) cells. MET degradation by these pathways is prevented when SPRY2 is bound to MET

Back to article page